694529-76-5

Upstream product

• 57233-86-0 d-(+)-α-methyl-4-nitrobenzylamine hydrochloride 
• 694529-38-9 (R)-[1-(4-nitrophenyl)ethyl]carbamic acid t-butyl ester 
• 262368-44-5 (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester 
• 910534-76-8 (R)-[1-(4-methanesulfonylaminophenyl)ethyl]carbamic acid t-butyl ester 

Downstream Products

• 910534-78-0 (R)-3-(4-t-butylphenyl)-N-[1-(4-methanesulfonylaminophenyl)ethyl]propionamide 
• 1207961-08-7 (R)-N-(4-(1-[3-(4-triethylsilanylbenzyl)thioureido]-ethyl)phenyl)methanesulfonamide 
• 1207961-06-5 (R)-N-[4-(1-(3-[4-(ethyldimethylsilanyl)benzyl]thioureido)ethyl)phenyl]methanesulfonamide 

Relevant academic research and scientific papers

NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention

Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists

A series of chain-branched 1,3-dibenzylthiourea derivatives were synthesized, and tested their antagonist activity against vanilloid receptor 1. Chain-branching led to a significant change in the mode of action and the potency. (R)-Methyl or ethyl-branched 1,3-dibenzylthiourea derivatives showed the most potent antagonist activity up to the IC50 value of 0.05 μM which is 10-fold more potent than capsazepine.